Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families

Xueying Liang, Ruth M Pfeiffer, Wen-Qing Li, Myriam Brossard, Laura S Burke, William Wheeler, Donato Calista, Maria Concetta Fargnoli, Paola Ghiorzo, Ketty Peris, Giovanna Bianchi-Scarra, Valerie Chaudru, Diana Zelenika, Dennis Maeder, Laurie Burdette, Meredith Yeager, Stephen Chanock, Maria Teresa Landi, Florence Demenais, Margaret A Tucker, Alisa M Goldstein, Xiaohong R Yang, Xueying Liang, Ruth M Pfeiffer, Wen-Qing Li, Myriam Brossard, Laura S Burke, William Wheeler, Donato Calista, Maria Concetta Fargnoli, Paola Ghiorzo, Ketty Peris, Giovanna Bianchi-Scarra, Valerie Chaudru, Diana Zelenika, Dennis Maeder, Laurie Burdette, Meredith Yeager, Stephen Chanock, Maria Teresa Landi, Florence Demenais, Margaret A Tucker, Alisa M Goldstein, Xiaohong R Yang

Abstract

Dysplastic nevi (DN) is a strong risk factor for cutaneous malignant melanoma (CMM), and it frequently occurs in melanoma-prone families. To identify genetic variants for DN, we genotyped 677 tagSNPs in 38 melanoma candidate genes that are involved in pigmentation, DNA repair, cell cycle control, and melanocyte proliferation pathways in a total of 504 individuals (310 with DN, 194 without DN) from 53 melanoma-prone families (23 CDKN2A mutation positive and 30 negative). Conditional logistic regression, conditioning on families, was used to estimate the association between DN and each single-nucleotide polymorphism (SNP) separately, adjusted for age, sex, CMM, and CDKN2A status. P-values for SNPs in the same gene were combined to yield gene-specific P-values. Two genes, CDK6 (cyclin-dependent kinase 6) and XRCC1, were significantly associated with DN after Bonferroni correction for multiple testing (P=0.0001 and 0.00025, respectively), whereas neither gene was significantly associated with CMM. Associations for CDK6 SNPs were stronger in CDKN2A mutation-positive families (rs2079147, Pinteraction=0.0033), whereas XRCC1 SNPs had similar effects in mutation-positive and -negative families. The association for one of the associated SNPs in XRCC1 (rs25487) was replicated in two independent data sets (random-effect meta-analysis: P<0.0001). Our findings suggest that some genetic variants may contribute to DN risk independently of their association with CMM in melanoma-prone families.

Conflict of interest statement

Conflict of Interest: None.

References

    1. Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mac KP, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol. 2000;114:28–33.
    1. Cannon-Albright LA, Meyer LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM) Cancer Res. 1994;54:6041–4.
    1. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, et al. Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum Genet. 2008;16:1135–41.
    1. Dudbridge F, Koeleman BP. Rank truncated product of P-values, with application to genomewide association scans. Genet Epidemiol. 2003;25:360–6.
    1. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965–71.
    1. Fargnoli MC, Spica T, Sera F, Pellacani G, Chiarugi A, Seidenari S, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2006;98:144–5. author reply 5–6.
    1. Figl A, Scherer D, Nagore E, Bermejo JL, Dickes E, Thirumaran RK, et al. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Mutat Res. 2009;661:78–84.
    1. Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V, et al. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Exp Dermatol. 2012;21:718–20.
    1. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005;14:2208–12.
    1. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000;92:1006–10.
    1. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15–21.
    1. Karahalil B, Bohr VA, Wilson DM., 3rd Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31:981–1005.
    1. Landi MT, Baccarelli A, Calista D, Pesatori A, Fears T, Tucker MA, et al. Combined risk factors for melanoma in a Mediterranean population. Br J Cancer. 2001;85:1304–10.
    1. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005;97:998–1007.
    1. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34:816–34.
    1. Liang XS, Pfeiffer RM, Wheeler W, Maeder D, Burdette L, Yeager M, et al. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations. Int J Cancer 2011
    1. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59:2557–61.
    1. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.
    1. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res. 2002;62:152–5.
    1. Pfeiffer RM, Gail MH, Pee D. Inference for covariates that accounts for ascertainment and random genetic effects in family studies. Biometrika. 2001;88:16.
    1. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 1998;395:237–43.
    1. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer. 2002;94:3192–209.
    1. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene. 2003;22:3042–52.
    1. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;277:1439–44.
    1. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56:645–6.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다